News | September 13, 2013

FDA Committee Reviews Innovative CardioMEMS Heart Failure Monitor

Panel also reviews Medtronic ICD expansion for heart failure


September 13, 2013 – The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee will review two new technologies to help treat heart failure (HF) Oct. 8-9, 2013.

On Oct. 9, the committee will discuss, make recommendations and vote on information related to the premarket approval application for CardioMEMS Inc. Champion HF monitoring system. The system is a permanently implantable pressure measurement system designed to provide daily pulmonary arterial pressure measurements including systolic, diastolic and mean pulmonary arterial (PA) pressure. These measurements are used to guide treatment of congestive heart failure.

The system consists of an implantable sensor containing a three- dimensional coil and pressure-sensitive capacitor encased between two wafers of fused silica. The coil (inductor) electromagnetically couples to the sensor and allows the remote measurement of the resonant frequency of the inductive/capacitive circuit. This allows for wireless communication with the sensor and eliminates the need for an onboard source of energy, such as a battery. 

The device is delivered within the distal pulmonary artery. There are two versions of the delivery system. The first includes a hydrophilic coating on the distal portion of the catheter shaft and the second has no coating on the catheter shaft. The delivery system (with HF sensor) is introduced over a guidewire through a sheath. Tether wires connect the sensor to the delivery system until the physician determines that the sensor is properly positioned within the distal pulmonary artery. Once the sensor is in position, the tether wires are withdrawn, releasing the sensor.

The electronics unit (interrogator) and database contain hardware and software to acquire and process signals from the sensor, provides a system interface for both patients and clinicians, and transfers PA measurements to a database for review by medical professionals. The database is a Web-based server that contains software, which receives data transmitted from the electronics unit, and presents the data for review by medical professionals.    

On Oct. 8, the committee will review and make recommendations related to the expansion of heart failure indications to all market-approved Medtronic cardiac resynchronization therapy-pacemaker and cardiac resynchronization therapy-defibrillator devices.

The requested expansion in indications for use was studied under the Block HF trial. The trial was a prospective, multisite, randomized, double-blinded, parallel-controlled investigational device exemption study. The primary objective of the trial was to demonstrate that the time until the first event of all-cause mortality, heart-failure- related urgent care, or a significant increase in left ventricular end systolic volume index for subjects programmed to biventricular pacing is superior to that of subjects programmed to right ventricular pacing.     

The meeting will be held each day from 8 a.m. to 6 p.m. at the Hilton Washington, D.C., North/Gaithersburg, Salons A-D, 620 Perry Pkwy., Gaithersburg, Md.

For more information:

Related Content

First Canadian Patient Implanted With CardioMEMS Heart Failure Sensor
News | Heart Failure| June 23, 2017
In a Canadian first, a medical team has implanted the wireless CardioMEMS HF device inside a heart failure patient. The...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve ar
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
Sponsored Content | Videos | Business| June 06, 2017
Andrea Natale, M.D., FACC, FHRS, FESC, executive medical director, Texas Cardiac Arryhthmia Institute at St.
Biosense Webster's multi-electrode RF ablation balloon

The most popular technology in May was the first data released on Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | June 01, 2017 | Dave Fornell
June 1, 2017 — Here is the list of the most popular pieces of content on the Diagnostic and Interventional Cardiology
Infab Introduces Revolution Lead Aprons
Technology | Radiation Dose Management| June 01, 2017
June 1, 2017 — Infab Corp.
Sponsored Content | Videos | Implantable Cardioverter Defibrillators (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
BioVentrix Announces Germany's First Revivent TC TransCatheter Ventricular Enhancement Procedure
News | Heart Failure| May 31, 2017
BioVentrix Inc. recently announced the first clinical use of its closed-chest Revivent TC TransCatheter Ventricular...
Overlay Init